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This work evaluates the central nervous effects in ICR strain mice of 2-ethylthio-7-methyl-4-(4-
methylphenyl)pyrazolo[1,5-a][1,3,5]triazine (MH4b1), a compound obtained by an efficient one-step 
reaction of S,S-diethyl 4-methylbenzoylimidodithiocarbonate with 5-amino-3-methyl-1H-pyrazole, in 
order to assess its neuro-pharmacological profile. The tests applied were: maximal electroshock seizure 
(MES), pentylenetetrazole (PTZ) seizures, forced swimming, plus maze, marble burying, sleeping time, 
rota-rod and catalepsy. In addition, MH4b1 binding to the benzodiazepine site of the GABA-A receptor 
and MH4b1 inhibition of monoamine oxidase (MAO) subtypes A and B were evaluated. MH4b1 showed 
anticonvulsant effects in a dose dependent manner (30-300 mg/kg, p.o.) against MES and inhibition of 
MAO-B (IC50: 24.5 µM) without activity at the benzodiazepine site. These data suggest that MH4b1 has 
anticonvulsant properties related to MAO-B inhibition.
Uniterms: Pyrazolo-triazine/anticonvulsant profile. Anticonvulsants/experimental study. Monoamine 
oxidase/inhibitors.
Este trabalho avalia o efeito do 2-etiltio-7-metil-4-(4-metilfenil)pirazol[1,5-a][1,3,5]triazina 
(MH4b1) no sistema nervoso central de camundongos ICR. O MH4b1 foi obtido por a reação de 
4-metilbenzoilimidoditiocarbonato de S,S-dietil e 5-amino-3-metil-1H-pirazol em uma única etapa. 
O perfil neurofarmacológico foi realizado por testes de convulsão induzida por eletrochoque (MES) 
e pentilenotetrazol (PTZ) e por testes de nado forçado, labirinto em cruz, esconder as esferas, sono 
barbitúrico, rota-rod e catalepsia. Também foi avaliada a união do MH4b1 ao o local de ligação de 
benzodiazepínicos do receptor GABA-A e a capacidade inibitória do MH4b1 sobre a monoaminoxidase 
(MAO) A e B. O MH4b1 mostrou efeito anticonvulsivante dependente da dose (30-300 mg) no teste do 
MES e apresentou atividade inibitória da MAO-B (CI50: 24.5 µM) sem interagir com o local de ligação 
de benzodiazepínicos do receptor. Os resultados sugerem que o MH4b1 tem atividade anticonvulsivante 
relacionada com a inibição da MAO-B.
Unitermos: Pirazol-triazina/perfil anticonvulsivante. Anticonvulsivantes/estudo experimental. 
Monoaminoxidase/inibidores.
INTRODUCTION
The pyrazolo[1,5-a][1,3,5]triazine system has been a 
pharmacological structure for the development of drugs that 
are potentially useful for a wide range of disorders, including 
asthma (Junien et al., 1998), cancer (Nie et al., 2008; 
Popowycz et al., 2009), inflammatory (el-Hawash et al., 
1998), thrombogenic (Raboisson et al., 2002) and affective 
disorders such as major depression and pathological 
anxiety (Gilligan et al., 2009). An efficient method for 
the preparation of pyrazolo[1,5-a][1,3,5]triazines by the 
interaction of S,S-diethyl aroyliminodithiocarbonates 
with 5-amino-3-methylpyrazole to obtain novel 4-aryl-
2-ethylthio-7-methylpyrazolo[1,5-a][1,3,5]triazines 
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was developed (Insuasty et al., 2006a,b). However, the 
pharmacological profiles of these compounds have not been 
assessed until now.
The GABA-A receptor and monoamine oxidases 
A and B are targets in the central nervous system for 
compounds with potential anxiolytic, anticonvulsant, 
antidepressant and/or anti-Parkinsonian properties 
(Trincavelli et al., 2012; Kulkarni et al., 2009; Youdim 
et al., 2006) In view of the global and increasing impact 
of major affective, neurologic and neurodegenerative 
disorders, there is a need to look for new pharmacological 
alternatives for their treatment.
Pyrazolo-triazines are sources of potential drugs 
for the treatment and/or prevention of disorders of the 
central nervous system, including anxiety, convulsions and 
cognition enhancement. These effects seem to be related 
to their affinity for GABA-A receptors (Atack, 2011a,b; 
Guerrini et al., 2010). Furthermore, adenosine A(1) receptor 
antagonism of some of these compounds could add to their 
potential value in the treatment of cognitive dysfunction 
(Harvey et al., 2012). Also, corticotropin-releasing 
factor antagonism could explain anxiolytic properties 
some of them possess (Li et al., 2003). In addition, some 
pyrazolotriazine derivatives have shown affinity for central 
monoamine oxidases (Carotti et al., 2007), target molecules 
in the search for agents to treat neuroprotective and/or 
affective disorders (Moussa et al., 2006).
This work presents the effects of 2-ethylthio-7-
methyl-4-(4-methylphenyl)pyrazolo[1,5-a][1,3,5]triazine 
(MH4b1) in screening models in mice and shows its profile 
as a potential anticonvulsant agent with MAO-B properties.
MATERIAL AND METHODS
MH4b1 synthesis
MH4b1 was synthetized by heating a solution 
of equimolar amounts of S,S-diethyl 4-methyl-
benzoylimidodithiocarbonate 1 (0.003 mol) and 5-amino-
3-methylpyrazole 2 (0.003 mol) in dimethylformamide 
(DMF, 2 mL) under reflux for 0.5–1.5 h, according to 
the method described by Insuasty et al. (2006). The solid 
product was precipitated by the addition of cold water 
to the reaction mixture. The precipitate was collected by 
filtration and purified by column chromatography on silica 
gel using a mixture of hexanes/ethyl acetate (4:1) as eluent.
Animals
The Animalarium in the Pharmacy Department of 
the National University of Colombia provided male 7–9 
week-old ICR strain albino mice, between 20 and 30 g, 
which were maintained under conditions of controlled 
temperature and humidity with a photoperiod of 12 hours 
light/darkness and free access to food and water. The 
animals were subjected to a fasting period of no more 
than six hours during the test day to prevent effects on the 
convulsive threshold. Six to seven animals per treatment 
and per dose were used, except in the preliminary 
observational Irwin test, where three animals were used 
(Roux et al., 2003). A digital video camera was used to 
examine the behaviour of each animal in the absence of the 
experimenter. All procedures were conducted following 
the care principles for the management of laboratory 
animals. The Ethics Committee of the Faculty of Science 




This test was used to assess the preliminary effects 
of the drug on the behavioural and physiological states 
of the mice and to select the screening dose to be used 
in the following in vivo models. Animals were treated 
with 30, 60 and 100 mg/kg, p.o. of MH4b1 or vehicle 
(control), in a mixture of glycerine (10%), propylene 
glycol (10%), polysorbate (5%) and distilled water 
(75%) in a volume of 0.1 mL/10 g, p.o. The animals were 
observed at 0, 15, 30, 60, 120 and 180 min, and 24 h after 
administration. The presence or absence of the following 
effects was analysed: mortality, seizure, erection of the tail 
(Straub sign), sedation, excitation, abnormal gait, jumps, 
motor incoordination, abdominal torsion, piloerection, 
stereotypy, ticks, and increase or decrease in respiration 
(Roux et al., 2003).
Maximum electroshock seizure (MES)
This test was used to identify potentially effective 
agents in preventing tonic clonic seizures. Groups of 
seven animals were treated with MH4b1 (100 mg/kg, 
p.o.), sodium phenytoin (positive control, 20 mg/kg, p.o.) 
or vehicle (negative control) one hour prior to exposure 
to an electric shock of 50 mA, 60 Hz and 130 ms through 
corneal electrodes (A13-65 Coulbourn Instruments 
stimulator). A protective effect was assumed when the drug 
prevented the tonic extension of the hind legs at an angle 
greater than 45 degrees (Swinyard et al., 1989).
Seizures induced by pentylenetetrazole (PTZ)
This test was used to detect potentially effective 
agents  to  prevent  absence seizures .  Groups of 
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seven animals treated one-hour prior with MH4b1 
(100 mg/kg, p.o.), clonazepam (positive control, 
0.5 mg/kg, p.o.) or vehicle were administered PTZ 
(GABA antagonist, 85 mg/kg, s.c.). Animals that did not 
show clonic seizures in their heads, backs or limbs for 
more than five seconds over the 30-minute observation 
period after PTZ administration were considered to be 
protected (Swinyard et al., 1989).
Plus maze
This test was used to detect potentially effective 
anxiolytic agents. Animals (six per group) were treated 
first with MH4b1 (100 mg/kg, p.o.), diazepam (positive 
control, 0.5 mg/kg, i.p.) or vehicle. After one hour, animals 
were individually placed into the central area (5x5 cm) of 
the plus maze platform formed by two opposing open arms 
(30x5x25 cm) and two opposing closed arms (30x5x25). 
The percentage of time that a mouse remained in the open 
arms during five minutes was recorded (Lister, 1987).
Marble burying
This test was used to detect potentially effective 
anxiolytic agents (Njung’e, Handley, 1991). Animals 
(s ix per  group) were t reated f i rs t  with MH4b1 
(100 mg/kg, p.o.), clonazepam (positive control, 
0.5 mg/kg, i.p.) or vehicle. After one hour, animals were 
individually placed into an acrylic clear box measuring 
30×20×15 cm containing sawdust bedding that was 4 cm 
in depth, with twenty-five marbles 2 cm in diameter. 
Testing was conducted for a 15-min period. The number 
of marbles buried was recorded. Marbles were considered 
buried if at least one half of their surface was covered 
with bedding.
Rota-rod
This test was used to detect potentially neurotoxic 
agents (Swinyard et al., 1989; Löscher, Nolting, 1991). 
Three groups of six animals were trained to maintain 
their balance on an axle three cm in diameter powered by 
a small engine at 12 rpm. Mice were previously trained 
on the rota-rod for 3 min at a speed of 12 rpm. Mice that 
were able to remain on the rod for this time period were 
selected. For testing, the animals were placed on the rota-
rod one hour after administration of MH4b1 (100 mg/kg, 
p.o.), clonazepam (0.5 mg/kg, p.o.) or control (vehicle, 
0.01 mL/g). The time that each animal was able to maintain 
its balance upon the rota-rod was recorded.
Barbiturate-induced sleep period
This test was used to detect agents with sedative 
effects. Animals (three groups of six) were treated first 
with MH4b1 (100 mg/kg, p.o.), diazepam (0.5 mg/kg, 
i.p.) or vehicle and were then treated with pentobarbitone 
(40 mg/kg, i.p.). Sleep periods were recorded from the 
moment the animals completely lost their gait until the 
moment gait was recovered (Lapa et al., 2002).
Forced swimming (FST)
This test was used to detect agents with antidepressant 
potential. Animals (three groups of six) were treated with 
MH4b1 (100 mg/kg, p.o.), imipramine (positive control, 
20 mg/kg, i.p.), or vehicle. After one hour, the animals 
were individually placed into plastic cylinders (35x24 cm) 
containing water (25 °C) to a height of 13.5 cm. The total 
time immobile, defined as movements only necessary for 
the animal to stay afloat, was recorded over five minutes 
(Porsolt et al., 1977).
Catalepsy test
This test is used to detect anti-extrapyramidal drugs, 
such as anticholinergic and anti-Parkinsonian agents 
(Abraham, 2003). Three groups of six animals were 
treated with either MH4b1 (100 mg/kg, p.o.), biperiden 
(reference drug, 3 mg/kg, i.p. [Makoto et al., 1979]) or 
vehicle (control) and then, after one hour, the animals 
were administered haloperidol (2 mg/kg, i.p.). The time 
required for each animal to return to a natural position 
with its four legs on the floor after placing his forepaws 
on a metal bar situated four inches above floor level was 
determined (Costall, Naylor, 1974).
In vivo dose-response effect of MH4b1
According to the results obtained in the in vivo 
screening test, MES was the test selected to perform a dose 
response experiment. Groups of mice treated with 30, 100 
and 300 mg/kg p.o. of MH4b1 were subjected to the same 
protocol described previously.
Determination of monoamine oxidase (MAO) 
isoform activity
The effects of MH4b1 on MAO-A and MAO-B 
activities were studied using a crude rat brain mitochondrial 
suspension as a source of enzymes. Serotonin (100 µM) 
and 4-dimethylaminophenethylamine (5 µM) were used 
as selective substrates for MAO-A and -B, respectively. 
The methodological details are described in Hurtado 
et al., (2004). Substrates and their metabolites were 
detected by HPLC-ED after 10 and 8 minutes of reaction 
to the MAO-A and MAO-B isoforms, respectively. The 
IC50 value was calculated from at least two independent 
experiments, each performed in triplicate.
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Binding to the benzodiazepine site on the 
GABA-A receptor
An assay was performed to estimate the level of 
inhibition produced by MH4b1 on the binding of tritiated 
flunitrazepam (3H-FNZ) to the GABA-A receptor in 
synaptosomal membranes of rat cerebral cortex containing 
0.2–0.4 mg of protein (Fernández et al., 2004). The 
membranes were suspended in the presence of MH4b1 
(300 µM) and radiolabeled ligand (0.6 nM) in a final 
volume of 1 mL of buffer solution (25 mM Tris-HCl, pH 
7.3). The incubation was carried out at 4 °C for 1 hour. This 
assay was performed in triplicate. The displacement of 3H 
FNZ by MH4b1 was determined using liquid scintillation.
Experimental design and data analysis
The experiments followed a randomized design with 
6–7 replicates per treatment. The results are expressed as 
the arithmetic mean values ± standard error of the mean 
(SEM) in all tests except the MES and PTZ tests, which 
are expressed as the number of animals with or without 
convulsion. The Fisher test was applied to the MES and 
PTZ tests due to their dichotomous responses. One-way 
analyses of variance followed by Tukey’s comparison test 
was applied to the plus maze, marble burying, sleeping 
time, forced swimming, rota-rod and catalepsy tests. A 
semi-logarithmic regression analysis was applied to the 
MAO-inhibition experiments in order to determine the 
inhibitory concentration 50 (IC50) values. The data were 
analysed with the statistical package Graph Pad®. A p value 
of 0.05 was assumed to be statistically significant.
RESULTS
Identification of MH4b1 
Its melting point value (112 ºC) as well as infrared, 
1H and13C magnetic resonance spectra were consistent 
with the proposed structure of 2-ethylthio-7-methyl-4-(4-
methylphenyl)pyrazolo[1,5-a][1,3,5]triazine (Figure 1, 
molecular weight: 284). The structure of this compound 
was additionally corroborated by X-ray diffraction 
analysis (Insuasty et al., 2006a,b).
Data: Green solid, mp 112 °C (63%). 1H NMR 
(400 MHz, DMSO): δ 1.40 (t, 3H, CH3), 2.45 (s, 3H, 
7-CH3), 3.19 (c, 2H, CH2), 6.33 (s, 1H, 8-H), 7.42 (t, 2H, 
Hm), 8.58 (d, 2H, Ho). 13C NMR (DMSO): δ 13.6 (CH3), 
13.8 (7-CH3), 20.5 (CH2), 93.3 (C-8), 126.5 (Ci), 128.3 
(Cm), 130.4 (Co), 143.1 (Cp), 150.5 (C-4), 151.3 (C-8a), 
156.8 (C-7), 164.6 (C-2). EIMS: m/z: 284 (M+, 100), 
269 (22), 251 (57), 139 (27%), 118 (24), 70 (15), 39 (15) 
(Figures 1, 2).
In vivo tests
No obvious neurological or autonomic changes 
were observed in the Irwing test in treated animals, even 
at 100 mg/kg p.o. of MH4b1. Therefore, the 100 mg/kg 
dose of this compound was selected for use in screening 
tests. According to the guidelines to screening compounds 
administered p.o., a 1 h interval was chosen between 
administration of the compound and each behavioural test 
(Voguel, 2002).
MH4b1 showed significant effects in the MES and 
sleep period tests, but was not active in the PTZ, plus 
maze, marble burying, forced swimming, rota-rod and 
FIGURE 1 - Schematic synthesis of 2-ethylthio-7-methyl-4-(4-
methylphenyl)pyrazolo [1,5-a][1,3,5]triazine (MH4b1).
FIGURE 2 - 2-Ethylthio-7-methyl-4-(4-methylphenyl)
pyrazolo[1,5-a][1,3,5]triazine (MH4b1), a compound obtained 
by an efficient one-step reaction from S,S-diethyl 4-methyl-
benzoylimidodithiocarbonate and 5-amino-3-methylpyrazole, 
displayed anticonvulsant properties in mice.
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TABLE I – Effects of MH4b1 in screening behavioural models in ICR mice. *: p<0.05. NS: Not significant. ǂDose (mg/kg). MES: 
maximal electroshock seizures. PTZ: pentylenetetrazole
Test Effect Treatment Doseǂ n Result p value
MES Hind limb extension
Control (-) 7 7/7 (-)
Phenytoin 20 7 0/7 *
MH4b1 100 7 2/7 *
PTZ Myoclonus
Control (-) 7 7/7 (-)
Clonazepam 0.5 7 0/7 *
MH4b1 100 7 7/7 NS
Plus maze Percent time/frequency in open arms
Control (-) 6 21±5/37±5 (-)
Diazepam 0.5 6 46±5/51±3 *
MH4b1 100 6 39±6/36±6 NS
Marble burying No. of buried marbles 
Control (-) 6 21±5 (-)
Clonazepam 0.5 6 46±5 *
MH4b1 100 6 39±6 NS
Rota rod Time on rota rod (s)
Control (-) 6 18±3 (-)
Clonazepam 0.5 6 8±2 *
MH4b1 100 6 18±2 NS
Sleeping period Time asleep (min)
Control (-) 6 17±2 (-)
Diazepam 0.5 6 34±2 *
MH4b1 100 6 32±5 *
Forced swimming Time immobile (s)
Control (-) 6 172±19 (-)
Imipramine 0.5 6 65±12 *
MH4b1 100 6 207±12 NS
Catalepsy Time cataleptic (min)
Control (-) 6 683±33 (-)
Biperiden 3 6 417±82 *
MH4b1 100 6 669±35 NS
FIGURE 3 - Effect of MH4b1 (30, 100 and 300 mg/kg, p.o) in 
the MES test in ICR mice (50 mA, 60 Hz, 130 ms), *:p<0.05 
against control (vehicle). Phenytoin (20 mg/kg p.o) was used 
as a reference.
catalepsy tests. The effect of MH4b1 was dose dependent 
(30 – 300 mg/kg, p.o.) in the MES test (Table I, Figure 3). 
The reference drugs gave positive results in all models.
In vitro tests
MH4b1 showed a selective inhibitory activity 
toward MAO-B (Figure 4). The IC50 obtained against 
MAO-B was 24.5 [17.1 – 34.2] µM. The percent inhibition 
of MAO-A was only 16% at the highest concentration 
tested (100 µM). MH4b1 did not show activity at the 
benzodiazepine binding site of the GABA-A receptor, not 
even at 300 mM (data not shown).
DISCUSSION
The results of this study show that MH4b1 exerted 
significant effects in the MES and sleeping period 
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screening tests and selective activity against MAO-B, 
whereas it lacked effect in pentylenetetrazole, plus maze, 
marble burying, rota-rod and catalepsy tests, and is devoid 
of binding to the benzodiazepine site of the GABA-A 
receptor.
The duration of the tonic hindlimb extensor phase 
in the MES test is a parameter used by some researchers 
in order to evaluate seizure severity and the protection 
conferred by a potential anticonvulsant drug (Manocha 
et al., 2003). The latency period until seizure induced 
by pentilenetetrazol is considered in a similar fashion 
(Roeloffs et al., 2008). However, the predictive value of a 
potential anticonvulsant only considering the capacity to 
prevent the seizure could be a better parameter, because the 
anticonvulsant should not only be able to decrease the length 
of time of an experimental seizure but also prevent it. In the 
search for anti-absence drugs for instance, drugs should 
prevent the PTZ induced seizures (Löscher et al., 1991).
In this work, MH4b1 was able to prevent the MES 
but not PTZ seizures, suggesting that GABA-A and T 
calcium channel binding properties were not implicated 
in the mechanisms of action of MH4b1. Agents with 
this mechanism of action, like benzodiazepines and 
valproic acid, protect against PTZ seizures (White, 1999; 
Macdonald, Kelly, 1995).
MH4b1 could have an anticonvulsant activity 
against tonic clonic seizures, considering that MES is a 
useful screening model to identify drugs for this kind of 
seizure (Swinyard et al., 1989). Some anticonvulsants like 
lamotrigine and zonizamide are effective against MES, 
preventing tonic clonic seizures in man and displaying 
inhibitory effects against MAO-B (Muck-Seler et al., 
2008; Sonsalla et al., 2010). This property suggests a 
neuroprotective effect due to a reduction in reactive 
oxygen species generated in the central nervous system 
by this enzyme, a characteristic that could be of special 
interest in searching for modern anticonvulsant drugs 
(Marzo et al., 2004).
MAO inhibition has been described as a possible 
anticonvulsant mechanism of action of some agents. 
In addition, MAO inhibition is also implied in sedative 
properties (Kohli et al., 1967). This fact is in accordance 
with the increase in the sleeping period obtained with 
MH4b1 in pentobarbitone tests in mice. Anticonvulsant 
GABA-A agonists, like benzodiazepines drugs, protect 
against MES and PTZ seizures and increase time latency 
and duration in pentobarbitone tests (Lapa et al., 2002). 
The lack of an effect of MH4b1 against pentylenetetrazole 
and in the plus maze tests supports the idea that MH4b1 
does not act at the benzodiazepine site of the GABA-A 
receptor (Fradley et al., 2007; Duarte et al., 2008). This 
presumption was confirmed in the in vitro test with tritiated 
flunitrazepam (3H-FNZ).
Interactions at voltage dependent sodium channels 
are frequently observed with drugs that are effective in the 
MES model (Holmes and Zhao, 2008). Such is the case 
with anticonvulsants like lamotrigine and zonizamide 
(Vohora et al., 2010), which, in addition, possess MAO-B 
inhibitory properties. Therefore, this mechanism of action 
should be considered in future experiments with MH4b1.
It is also interesting that at the dose tested, MH4b1 
did not affect motor coordination according to the rotarod 
test, whereas clonazepam, the reference drug test, did. 
This could suggest a good safety profile for MH4b1 as an 
anticonvulsant (Kamiński et al., 2008). Moreover, the lack 
of activity of MH4b1 in the haloperidol induced catalepsy 
test could imply that this moiety does not have pivotal 
central anticholinergic properties. In addition, the negative 
results against forced swimming are in accordance with 
a MAO-B inhibitory profile, like that of deprenyl, which 
displays good activity against MAO-B at inactive doses 
in FST (Shimazu et al., 2005).
According to these results MH4b1, with a positive 
effect in the MES test but a negative effect in the PTZ test, 
along with a sedative but not anxiolytic or anti-depressant-
like profile, could be consistent with MAO-B inhibition 
properties, although another mechanism, like sodium 
channels antagonism, should be considered.
The structure of MH4b1 seems to show that 
the 4-methylphenyl moiety could play a key role in 
FIGURE 4 - Concentration-response curves of MH4b1 (10– 7 – 
10-4 M) against percent inhibition of MAO-A and MAO-B. Data 
are the mean ± S.E.M. *p<0.05.
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the anticonvulsant properties of this compound. The 
electron-releasing, steric and lipophilic characteristics 
of the substituent at position 4 of the aryl ring would be 
important for the activity of this pyrazolotriazine, but 
further structure activity relationship experiments are 
needed to verify this proposition.
CONCLUSION
In conclusion,  2-ethylthio-7-methyl-4-(4-
methylphenyl)pyrazolo[1,5-a][1,3,5]triazine (MH4b1) 
displays anticonvulsant effects in mice and selective 
inhibition of MAO-B. More experiments are needed in 
order to pinpoint its precise mechanism of action.
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